SciELO - Scientific Electronic Library Online

 
vol.33 número2Importance of killer immunoglobulin-like receptors in allogeneic hematopoietic stem cell transplantationCurrent status of PET/CT in the diagnosis and follow up of lymphomas índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Revista Brasileira de Hematologia e Hemoterapia

versão impressa ISSN 1516-8484

Resumo

CONCHON, Monika; FREITAS, Carla Maria Boquimpani de Moura; REGO, Maria Aparecida do Carmo  e  BRAGA JUNIOR, José Wilson Ramos. Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia. Rev. Bras. Hematol. Hemoter. [online]. 2011, vol.33, n.2, pp.131-139. ISSN 1516-8484.  http://dx.doi.org/10.5581/1516-8484.20110034.

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.

Palavras-chave : Leukemia, Myelogenous, Chronic, BCR-ABL Positive [drug therapy]; Drug toxicity; Drug interactions; Gastrointestinal tract [drug effects]; Drug resistance, neoplasm; Pyrimidines; Interferonalpha [administration & dosage]; Piperazines [therapeutic use]; Clinical Trial.

        · texto em Inglês     · Inglês ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons